Kinetics of silica nanoparticles in the human placenta

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Kinetics of silica nanoparticles in the human placenta. / Poulsen, Marie Sønnegaard; Mose, Tina; Maroun, Lisa Leth; Mathiesen, Line; Knudsen, Lisbeth E.; Rytting, Erik.

In: Nanotoxicology, Vol. 9, No. Supplement 1, 2015, p. 79-86.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Poulsen, MS, Mose, T, Maroun, LL, Mathiesen, L, Knudsen, LE & Rytting, E 2015, 'Kinetics of silica nanoparticles in the human placenta', Nanotoxicology, vol. 9, no. Supplement 1, pp. 79-86. https://doi.org/10.3109/17435390.2013.812259

APA

Poulsen, M. S., Mose, T., Maroun, L. L., Mathiesen, L., Knudsen, L. E., & Rytting, E. (2015). Kinetics of silica nanoparticles in the human placenta. Nanotoxicology, 9(Supplement 1), 79-86. https://doi.org/10.3109/17435390.2013.812259

Vancouver

Poulsen MS, Mose T, Maroun LL, Mathiesen L, Knudsen LE, Rytting E. Kinetics of silica nanoparticles in the human placenta. Nanotoxicology. 2015;9(Supplement 1):79-86. https://doi.org/10.3109/17435390.2013.812259

Author

Poulsen, Marie Sønnegaard ; Mose, Tina ; Maroun, Lisa Leth ; Mathiesen, Line ; Knudsen, Lisbeth E. ; Rytting, Erik. / Kinetics of silica nanoparticles in the human placenta. In: Nanotoxicology. 2015 ; Vol. 9, No. Supplement 1. pp. 79-86.

Bibtex

@article{edd1a25ae30c4880a985fa0d3898f694,
title = "Kinetics of silica nanoparticles in the human placenta",
abstract = "The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10(-6) ± 1.56 × 10(-6) cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.",
author = "Poulsen, {Marie S{\o}nnegaard} and Tina Mose and Maroun, {Lisa Leth} and Line Mathiesen and Knudsen, {Lisbeth E.} and Erik Rytting",
year = "2015",
doi = "10.3109/17435390.2013.812259",
language = "English",
volume = "9",
pages = "79--86",
journal = "Nanotoxicology",
issn = "1743-5390",
publisher = "Informa Healthcare",
number = "Supplement 1",

}

RIS

TY - JOUR

T1 - Kinetics of silica nanoparticles in the human placenta

AU - Poulsen, Marie Sønnegaard

AU - Mose, Tina

AU - Maroun, Lisa Leth

AU - Mathiesen, Line

AU - Knudsen, Lisbeth E.

AU - Rytting, Erik

PY - 2015

Y1 - 2015

N2 - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10(-6) ± 1.56 × 10(-6) cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

AB - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10(-6) ± 1.56 × 10(-6) cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

U2 - 10.3109/17435390.2013.812259

DO - 10.3109/17435390.2013.812259

M3 - Journal article

C2 - 23742169

VL - 9

SP - 79

EP - 86

JO - Nanotoxicology

JF - Nanotoxicology

SN - 1743-5390

IS - Supplement 1

ER -

ID: 137757810